Press Releases July 30, 2026 08:00 AM

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid schedules release of Q2 2026 financial results and operational update for August 12, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
PYPD

PolyPid Ltd., a biopharmaceutical company focused on localized drug delivery systems, announced it will release its Q2 2026 financial results and operational highlights on August 12, 2026, with a conference call and webcast scheduled to discuss the update.

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PYPD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • PolyPid will report Q2 2026 financial results before U.S. market open on August 12, 2026.
  • The Company specializes in long-acting, controlled-release drugs across surgical care and metabolic disease sectors.
  • PolyPid's lead product, D-PLEX100, recently met primary and key secondary endpoints in a Phase 3 trial for surgical site infections prevention.

PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will report its second quarter 2026 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:Wednesday, August 12, 2026Time:8:30 AM Eastern TimeConference Call:https://register-conf.media-server.com/register/BI9a8ec61eabe249f6a1e931836c819ce8Webcast:https://edge.media-server.com/mmc/p/3mbsv986


About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid's lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
[email protected]

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
[email protected]


Risks

  • Upcoming financial results may introduce volatility depending on earnings and operational performance.
  • Dependence on clinical trial success and regulatory approval for product commercialization poses ongoing risk.
  • Market acceptance and competition in pharmaceutical and surgical care sectors remain uncertain.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026